Effect of supplementation in treatment of women with polycystic ovary syndrome

Clinical trial of the effect of fish oil supplementation compared with the placebo on levels of gene expression related with glycemic control and inflammatory factors in women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201609305623N89

Enrollment

Registered

2016-10-01

Start date

2016-09-24

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: 1000 mg fish oil (Barij Essence, Kashan, Iran), twice a day, for 12 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), twice a day,

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with PCOS according to Rotterdam criteria aged 18 to 40 years

Exclusion criteria

Exclusion criteria: Pregnant women Diabetes and impaired glucose tolerance Hypo or hyperthyroidism Androgen-secreting tumor Hyperprolactinemia

Design outcomes

Primary

Measure	Time frame
PPAR-?. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;GLUT-1. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.	—

Secondary

Measure	Time frame
Interleukin 8. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Tumor necrosis factor alpha. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Interleukin 1. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;LDLR. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Lp(a). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;TGF-ß. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.	—

Measure

Time frame

Interleukin 8. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Tumor necrosis factor alpha. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Interleukin 1. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;LDLR. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Lp(a). Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;TGF-ß. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026